The three business components of Jubilant Pharmova Ltd, which include medicines, contract research and development services, and patented new therapies, make up this integrated global pharmaceuticals corporation.
Financial Results:
- Jubilant Pharmova Ltd. reported Total Income for Q4FY23 of ₹ 1,683 Crores up from ₹ 1,525 Crore year on year, a rise of 10%.
- Total Expenses for Q4FY23 of ₹ 1,786 Crores up from ₹ 1,420 Crores year on year, rise of 26%.
- Consolidated Net Profit of ₹ (101) Crores, down from ₹ 591 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹ (6.15), down from ₹ 3.74 in the same quarter of the previous year.